Definium Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Definium Therapeutics Inc 's ROA in the second quarter of 2026?
Definium Therapeutics Inc recorded a cumulative net loss of $-354 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -64.58%.

However, within the Consumer Non Cyclical sector 146 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4128, from total ROA ranking in the first quarter of 2026 at 4704.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	316.95 %	45.02 %	45.66 %	-25.91 %	-0.46 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-354	-238	-184	-168	-115
Return On Assets (TTM)	-64.58 %	-70.63 %	-60.23 %	-62.1 %	-39.3 %
DFTX's Total Ranking	# 4128	# 4704	# 4152	# 3931	# 3782
Total Assets (TTM) in million	1,113	401	440	237	267
Seq. Total Assets Change	177.33 %	-8.82 %	85.76 %	-11.24 %	-3.54 %
Seq. Net Income Change	-	-	-	-	-

DFTX's 5 Years Annual ROA >> Back to DFTX Management Effectiveness >> Compare DFTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 17
Sector	# 147
Overall	# 4040

Return On Assets Statistics
High	Average	Low
-26.64 %	-50.98 %	-73.32 %
(Mar 31 2025)		(Mar 31 2024)

Financial Statements
Definium Therapeutics Inc 's Assets	$ 1,113 million	DFTX's Balance sheet
Definium Therapeutics Inc 's Income	$ -159 million	Quarterly DFTX's Income Statement
DFTX's Income by Division		See DFTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2020) FY 2021
Y / Y Total Assets Change	45.66 %	142.61 %	-26.74 %	80.29 %	-
Total Assets in million	440	302	125	170	94
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-184	-109	-96	-57	-34
Annual Return On Assets	-41.76 %	-35.97 %	-76.87 %	-33.41 %	-35.99 %

DFTX's 5 Years Annual ROA >> Back to DFTX Management Effectiveness >> Compare DFTX ROA to its Competitors

More Return On Assets Ratios
DFTX's' Return on Assets at Yahoo Finance
Legal Cannabis Industry Return On Assets Trends and Statistics
Consumer Non Cyclical Sector Roa Statistics
Roa Trends for overall market
DFTX's Roa Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DFTX's Competitors
Subscribers only: Roa for Definium Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for DFTX's Customers

You may also want to know
DFTX's Roi	DFTX's Inventory Turnover Ratio	DFTX's Growth Rates	DFTX's Dividend Comparisons
	DFTX's Profitability Ratios	DFTX's Asset Turnover Ratio	DFTX's Dividend Growth
DFTX's Roe	DFTX's Valuation Ratios	DFTX's Financial Strength Ratios	DFTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Consumer Non Cyclical Sector

ROA

Date modified: 2026-09-12T06:26:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.